Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia
Background: Low-grade chronic inflammation, promoted by dysbiosis of the gut and oral microbiota, has been shown to contribute to individual susceptibility to atherosclerotic cardiovascular disease (ASCVD). High oral <i>Porphyromonas gingivalis</i> (<i>Pg</i>) and lower <i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/9/2144 |
| _version_ | 1827663274651418624 |
|---|---|
| author | Maria Cristina Curia Pamela Pignatelli Domenica Lucia D’Antonio Damiano D’Ardes Elena Olmastroni Luca Scorpiglione Francesco Cipollone Alberico Luigi Catapano Adriano Piattelli Marco Bucci Paolo Magni |
| author_facet | Maria Cristina Curia Pamela Pignatelli Domenica Lucia D’Antonio Damiano D’Ardes Elena Olmastroni Luca Scorpiglione Francesco Cipollone Alberico Luigi Catapano Adriano Piattelli Marco Bucci Paolo Magni |
| author_sort | Maria Cristina Curia |
| collection | DOAJ |
| description | Background: Low-grade chronic inflammation, promoted by dysbiosis of the gut and oral microbiota, has been shown to contribute to individual susceptibility to atherosclerotic cardiovascular disease (ASCVD). High oral <i>Porphyromonas gingivalis</i> (<i>Pg</i>) and lower <i>Fusobacterium nucleatum (Fn)</i> concentrations have been associated with clinical and experimental atherosclerosis. We assessed oral <i>Pg</i> and <i>Fn</i> abundance in very high-risk patients with previously diagnosed ASCVD, with or without heterozygous familial hypercholesterolemia (HeFH), in subjects with HeFH in primary prevention and in healthy subjects. Methods: In this cross-sectional study, 40 patients with previously diagnosed ASCVD (10 with genetically proven HeFH, and 30 without FH), 26 subjects with HeFH in primary prevention, and 31 healthy subjects were selected to quantify oral <i>Pg</i> and <i>Fn</i> abundance by qPCR and assess oral health status. Results: Compared to healthy subjects, patients with previously diagnosed ASCVD showed greater <i>Pg</i> abundance (1101.3 vs. 192.4, <i>p</i> = 0.03), but similar <i>Fn</i> abundance. HeFH patients with ASCVD had an even greater <i>Pg</i> abundance than did non-HeFH patients and healthy subjects (1770.6 vs. 758.4 vs. 192.4, respectively; <i>p</i> = 0.048). No differences were found in the levels of <i>Pg</i> and <i>Fn</i> abundance in HeFH subjects in primary prevention, as compared to healthy subjects. Conclusions: Greater oral <i>Pg</i> abundance is present in very high-risk patients with previously diagnosed ASCVD, with or without FH, suggesting a potential relationship with CV events. Future studies will assess the predictive value of <i>Pg</i> abundance measurement in ASCVD risk stratification. |
| first_indexed | 2024-03-10T00:39:32Z |
| format | Article |
| id | doaj.art-ab213e570e254e0d8c913b12aad00eb3 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T00:39:32Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-ab213e570e254e0d8c913b12aad00eb32023-11-23T15:09:52ZengMDPI AGBiomedicines2227-90592022-08-01109214410.3390/biomedicines10092144Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial HypercholesterolemiaMaria Cristina Curia0Pamela Pignatelli1Domenica Lucia D’Antonio2Damiano D’Ardes3Elena Olmastroni4Luca Scorpiglione5Francesco Cipollone6Alberico Luigi Catapano7Adriano Piattelli8Marco Bucci9Paolo Magni10Department of Medical, Oral and Biotechnological Sciences, Università degli Studi “Gabriele d’Annunzio” di Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral and Biotechnological Sciences, Università degli Studi “Gabriele d’Annunzio” di Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral and Biotechnological Sciences, Università degli Studi “Gabriele d’Annunzio” di Chieti-Pescara, 66100 Chieti, ItalyRegional Center for the Study of Atherosclerosis, Hypertension and Dyslipidemia, “SS Annunziata” Hospital—ASL, 66100 Chieti, ItalyEpidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, ItalyRegional Center for the Study of Atherosclerosis, Hypertension and Dyslipidemia, “SS Annunziata” Hospital—ASL, 66100 Chieti, ItalyRegional Center for the Study of Atherosclerosis, Hypertension and Dyslipidemia, “SS Annunziata” Hospital—ASL, 66100 Chieti, ItalyEpidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, ItalyMaster Course in Microsurgery in Odontostomatology, Saint Camillus International University for Health Sciences (Unicamillus), 00131 Rome, ItalyRegional Center for the Study of Atherosclerosis, Hypertension and Dyslipidemia, “SS Annunziata” Hospital—ASL, 66100 Chieti, ItalyEpidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, ItalyBackground: Low-grade chronic inflammation, promoted by dysbiosis of the gut and oral microbiota, has been shown to contribute to individual susceptibility to atherosclerotic cardiovascular disease (ASCVD). High oral <i>Porphyromonas gingivalis</i> (<i>Pg</i>) and lower <i>Fusobacterium nucleatum (Fn)</i> concentrations have been associated with clinical and experimental atherosclerosis. We assessed oral <i>Pg</i> and <i>Fn</i> abundance in very high-risk patients with previously diagnosed ASCVD, with or without heterozygous familial hypercholesterolemia (HeFH), in subjects with HeFH in primary prevention and in healthy subjects. Methods: In this cross-sectional study, 40 patients with previously diagnosed ASCVD (10 with genetically proven HeFH, and 30 without FH), 26 subjects with HeFH in primary prevention, and 31 healthy subjects were selected to quantify oral <i>Pg</i> and <i>Fn</i> abundance by qPCR and assess oral health status. Results: Compared to healthy subjects, patients with previously diagnosed ASCVD showed greater <i>Pg</i> abundance (1101.3 vs. 192.4, <i>p</i> = 0.03), but similar <i>Fn</i> abundance. HeFH patients with ASCVD had an even greater <i>Pg</i> abundance than did non-HeFH patients and healthy subjects (1770.6 vs. 758.4 vs. 192.4, respectively; <i>p</i> = 0.048). No differences were found in the levels of <i>Pg</i> and <i>Fn</i> abundance in HeFH subjects in primary prevention, as compared to healthy subjects. Conclusions: Greater oral <i>Pg</i> abundance is present in very high-risk patients with previously diagnosed ASCVD, with or without FH, suggesting a potential relationship with CV events. Future studies will assess the predictive value of <i>Pg</i> abundance measurement in ASCVD risk stratification.https://www.mdpi.com/2227-9059/10/9/2144atherosclerosis<i>Porphyromonas gingivalis</i><i>Fusobacterium nucleatum</i>cardiovascular diseaseheterozygous familial hypercholesterolemiasecondary cardiovascular prevention |
| spellingShingle | Maria Cristina Curia Pamela Pignatelli Domenica Lucia D’Antonio Damiano D’Ardes Elena Olmastroni Luca Scorpiglione Francesco Cipollone Alberico Luigi Catapano Adriano Piattelli Marco Bucci Paolo Magni Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia Biomedicines atherosclerosis <i>Porphyromonas gingivalis</i> <i>Fusobacterium nucleatum</i> cardiovascular disease heterozygous familial hypercholesterolemia secondary cardiovascular prevention |
| title | Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia |
| title_full | Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia |
| title_fullStr | Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia |
| title_full_unstemmed | Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia |
| title_short | Oral <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia |
| title_sort | oral i porphyromonas gingivalis i and i fusobacterium nucleatum i abundance in subjects in primary and secondary cardiovascular prevention with or without heterozygous familial hypercholesterolemia |
| topic | atherosclerosis <i>Porphyromonas gingivalis</i> <i>Fusobacterium nucleatum</i> cardiovascular disease heterozygous familial hypercholesterolemia secondary cardiovascular prevention |
| url | https://www.mdpi.com/2227-9059/10/9/2144 |
| work_keys_str_mv | AT mariacristinacuria oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT pamelapignatelli oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT domenicaluciadantonio oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT damianodardes oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT elenaolmastroni oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT lucascorpiglione oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT francescocipollone oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT albericoluigicatapano oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT adrianopiattelli oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT marcobucci oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia AT paolomagni oraliporphyromonasgingivalisiandifusobacteriumnucleatumiabundanceinsubjectsinprimaryandsecondarycardiovascularpreventionwithorwithoutheterozygousfamilialhypercholesterolemia |